Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Organisation › Details

Humabs BioMed S.A.

Humabs BioMed, a private biotechnology company based in Switzerland, is focused on discovering and developing fully human monoclonal antibodies to treat serious infections. Humabs BioMed is a spin-off of the Institute for Research in Biomedicine (IRB), which is affiliated with the Universita` della Svizzera Italiana (USI). Humabs' proprietary discovery technology - CellClone - platforms enable the isolation of antibodies that have passed natural selection by the human immune system in response to disease and can generally be developed rapidly without extensive lead optimization. Humabs has a portfolio of more than a dozen immunotherapy product candidates. The Company has partnered several of its programs with MedImmune and Novartis, and two of these programs are now in clinical development by these partners. Humabs is internally developing antibodies directed against hepatitis B virus and respiratory syncytial virus and metapneumovirus (RSV/MPV). These programs are currently in preclinical development. In collaboration with various public health agencies, Humabs is also developing a portfolio of immunotherapies against major public health threats, including MERS-CoV, dengue, Ebola, Rabies and Zika viruses. *

 

Period Start 2017-07-18 existent
  Group Vir Biotechnology (Group)
Products Industry therapeutic antibody
  Industry 2 virostatic agent
     
Region Region Switzerland_oo
  Country Switzerland
  Street 1 Via Mirasole
  City 6500 Bellinzona
  Tel +41-91-825-6380
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for »About Section«: Humabs BioMed S.A.. (7/18/17). "Press Release: Humabs BioMed and University of California, Berkeley Announce Publication of Data for Novel Antibody-based Assay to Detect Zika Virus Infection". Bellinzona & Berkeley, CA.
     
   
Record changed: 2023-07-10

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Vir Biotechnology (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px




» top